Recent ALZN News
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 06/11/2024 08:30:19 PM
- Form S-1 - General form for registration of securities under the Securities Act of 1933 • Edgar (US Regulatory) • 06/03/2024 08:30:49 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 05/31/2024 08:59:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/22/2024 08:30:23 PM
- Alzamend Neuro Announces Favorable Decision from Nasdaq Hearings Panel • Business Wire • 05/22/2024 12:00:00 PM
- Form 5 - Annual statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/16/2024 08:30:15 PM
- Alzamend Neuro Announces Initial Closing of Private Placement • Business Wire • 05/14/2024 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/13/2024 08:30:25 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 05/10/2024 09:06:26 PM
- Form 8-K/A - Current report: [Amend] • Edgar (US Regulatory) • 05/10/2024 08:30:31 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 05/10/2024 10:30:41 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/09/2024 08:30:28 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/09/2024 08:20:24 PM
- Alzamend Neuro Announces Agreement for Registered Direct Offering and Concurrent Private Placement for an Aggregate of up to $25 Million • Business Wire • 05/09/2024 12:00:00 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 05/07/2024 08:31:26 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/07/2024 08:30:33 PM
- Alzamend Neuro Announces Termination of At-the-Market Equity Offering Program • Business Wire • 05/07/2024 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/07/2024 09:30:33 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/02/2024 09:30:35 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/05/2024 09:30:27 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 12/15/2023 09:30:30 PM
- Alzamend Neuro Receives FDA “Study May Proceed” Notification for a Phase IIA Clinical Trial of AL001, a Next‑Generation Lithium Therapeutic Drug Candidate, in Post-Traumatic Stress Disorder Patients • Business Wire • 12/11/2023 01:00:00 PM
- Alzamend Neuro Receives FDA “Study May Proceed” Notification for a Phase IIA Clinical Trial of AL001, a Next‑Generation Lithium Therapeutic Drug Candidate, in Major Depressive Disorder Patients • Business Wire • 11/20/2023 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/16/2023 09:30:19 PM
- Alzamend Neuro Regains Compliance with Nasdaq’s Minimum Bid Price Requirement • Business Wire • 11/16/2023 01:00:00 PM
North Bay Resources Announces Composite Assays of 0.53 and 0.44 Troy Ounces per Ton Gold in Trenches B + C at Fran Gold, British Columbia • NBRI • Jun 18, 2024 9:18 AM
VAYK Assembling New Management Team for $64 Billion Domestic Market • VAYK • Jun 18, 2024 9:00 AM
Fifty 1 Labs, Inc Announces Acquisition of Drago Knives, LLC • CAFI • Jun 18, 2024 8:45 AM
Hydromer Announces Attainment of ISO 13485 Certification • HYDI • Jun 17, 2024 9:22 AM
ECGI Holdings Announces LOI to Acquire Pacific Saddlery to Capitalize on $12.72 Billion Market Potential • ECGI • Jun 13, 2024 9:50 AM
Fifty 1 Labs, Inc. Announces Major Strategic Advancements and Shareholder Updates • CAFI • Jun 13, 2024 8:45 AM